Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer ...

Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transa ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer ...

Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

Two immunotherapy treatment combinations were studied: PD-1/PD-L1 inhibitor and CTLA-4 inhibitor ... strong presence of B-cell receptor signaling pathways and tertiary lymphoid structures ...

Compass Therapeutics, Inc.’s CMPX share price has surged by 14.18%, which has investors questioning if this is right time to ...

I-MAB completed a workforce reduction as part of a Realignment Plan aimed at optimizing its operations following the pipeline reprioritization. The company reduced its workforce by approximately 27% ...